Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...
来自MSN18 分钟
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...
Medscape3 天
Thyroid Cancer Detections Due to More Screenings With GLP-1s
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
News Medical on MSN2 天
GLP-1RA initiation linked to new thyroid cancer diagnoses
Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
gastroenterologyadvisor3 天
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
Renal & Urology News4 天
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in Thyroid.
emjreviews.com3 天
Increased Short-Term Risk of Thyroid Cancer After Starting GLP-1RA Therapy
A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.
pharmaphorum3 天
EMA finds no evidence GLP-1 agonists cause thyroid cancer
it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can cause cancer of the thyroid. Six months ago, the Pharmacovigilance Risk ...
Healio1 天
Top in endocrinology: Notable weight loss with next-gen GLP-1; erectile dysfunction risk
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...